Skip to content

Recall of Dronabinol, USP, 2.5 mg and Ziprasidone Hydrochloride Capsules

Do you need help identifying the Recall of Dronabinol Capsules, USP, 2.5 mg and Ziprasidone Hydrochloride Capsules? In an era where medical science and pharmaceutical developments are key components of our everyday health and well-being, any disruption can lead to significant consequences. One such disruption has arisen with The Harvard Drug Group, LLC initiating a voluntary recall of a specific lot of Dronabinol Capsules, USP, 2.5 mg, and Ziprasidone Hydrochloride Capsules, 20 mg. This article aims to dissect the issue, discuss the potential risks involved, and provide guidance on what consumers should do if they have the recalled products.

Identifying the Recalled Products

The key to dealing with this situation effectively is to promptly identify if you have one of the recalled products. Both Dronabinol Capsules, USP, 2.5 mg and Ziprasidone Hydrochloride Capsules, 20 mg associated with this recall can be identified by the following details:

Product NamePackage DescriptionBrand NameLot
NDCExpiration Date
Capsules, USP, 2.5 mg
100 Unit Doses per
(10 x 10 blister packs)
Capsules, 20 mg
40 Unit Doses per
(10 x 4 blister packs)
See Label Image Below
Recall of Dronabinol Capsules USP 25 mg and Ziprasidone Hydrochloride Capsules

Physical descriptions are also available to help you identify the capsules. Ziprasidone Hydrochloride Capsules are lavender opaque cap and flesh opaque body capsules, imprinted with “RDY” on the cap and “356” on the body. On the other hand, Dronabinol Capsules are white and imprinted with “M2.”

What to Do if You Have the Recalled Product

If you identify the recalled products in your possession, stop using the product immediately. Return it to the place of purchase and consult with your healthcare provider as soon as possible. Be vigilant about any unusual symptoms or changes in health, as they might be linked to the incorrect medication.

For any further queries, Sedgwick, Inc., is providing customer support at 1-888-759-6904 or through email at

What Led to the Recall

The foundation of any pharmaceutical operation is the precise distribution and packaging of medications. Each drug is meticulously crafted, designed, and boxed to ensure the end-user receives the exact treatment they need. However, in this instance, there has been a packaging error at The Harvard Drug Group, a significant pharmaceutical player known under the brand names Major Pharmaceutical and Rugby Laboratories.

A customer complaint revealed that unit dose cartons labeled as Ziprasidone Hydrochloride Capsules, 20 mg, were found to contain blister packages labeled as and containing Dronabinol Capsules, USP, 2.5 mg, all from Lot T04769. As a consequence, the company has initiated a recall of all Lot T04769, Dronabinol Capsules, which may be found in outer cartons reading either Dronabinol Capsules, USP, 2.5 mg or Ziprasidone Hydrochloride Capsules, 20 mg.

The Risks Involved

While a simple packaging mix-up might sound minor, the consequences can be far-reaching. To understand why we must delve into the potential health hazards of mistakenly consuming Dronabinol when the intended medication was Ziprasidone Hydrochloride.

There are two main risks associated with this issue:

  1. Missing a dose of Ziprasidone, a vital medication for managing conditions like schizophrenia, bipolar disorder, and other forms of mental illness. An unexpected lack of this medication can exacerbate underlying health issues, resulting in mental instability, self-harm, harm to others, or the need for medical or psychiatric hospitalization.
  2. Inadvertently taking an unexpected dose of Dronabinol, a medication used for conditions such as anorexia associated with weight loss in AIDS patients and nausea and vomiting related to cancer chemotherapy. The unexpected introduction of Dronabinol into the system may cause mental and cognitive effects, impairing mental and/or physical abilities. This impairment could worsen symptoms in patients with mental illnesses and limit the ability to safely perform hazardous activities, such as driving a motor vehicle or operating machinery. The risks are particularly high for elderly patients or those taking other medications that affect mental function.

Understanding the Drugs Involved

To fully comprehend the potential implications of this mix-up, we need to look closer at the medications involved.

Ziprasidone Hydrochloride Capsules, 20 mg is an antipsychotic medication primarily used for the treatment of schizophrenia. It’s also used as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder.

Dronabinol Capsules, USP, 2.5 mg is a cannabinoid medication used for two main purposes: to treat anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS), and to combat nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

As you can see, these two drugs serve very different purposes, and are not interchangeable in a treatment plan.

Legal Rights and Recourse in Case of Adverse Reactions

In a situation like this, it’s essential to know your legal rights. If you or a loved one has experienced adverse reactions or any health complications due to this mix-up, legal recourse is available. You have the right to demand accountability and potentially seek compensation for any damages incurred due to this error.

As a law firm specializing in product liability and medical negligence, we are committed to helping victims navigate these complex processes. From assessing your case to representing your interests in court, our legal team is prepared to support you every step of the way.

The recall initiated by The Harvard Drug Group, LLC, involving Dronabinol and Ziprasidone Hydrochloride Capsules, highlights the importance of precision and diligence in the pharmaceutical industry. The potential consequences of such a mix-up underscore the seriousness of the issue.

If you suspect you have a recalled product or if you have experienced any problems that might be related to this issue, don’t hesitate to take action. Reach out to your healthcare provider, return the product, and consider seeking legal advice if you have been adversely affected.

Contact Us

We understand that dealing with the repercussions of a product recall can be stressful and challenging. Our law firm is ready to assist and guide you during this difficult time. If you believe you have been affected by this recall, please contact us for a consultation. Your well-being and peace of mind are our top priorities.